Our Focus Areas


  • Companies with platform underlying technologies that have or could create multiple drug candidates

  • Broad applicability and de-risk profile have positioned biotech platforms as great acquisition candidates

  • Platform technology addressing key unmet medical needs

Sgi Areasoffocus 2

Digital Health

  • There is an increasing shift from B2B-only offerings to direct-to-consumer (D2C), and B2B-and-D2C mixed offerings

  • Investors are doubling-down on their investments, prolonging the strong tailwind due to the COVID-19 pandemic

Sgi Areasoffocus 1

Medical Technology

  • There has been a recent spike in Medtech VC investment amidst the COVID-19 pandemic

  • Recent increased investment in Telehealth, Omics, and AI

  • Constantly in the look out for superior technology with clear potential to scale up

Sgi Areasoffocus 01

Creating Solutions Together.

Contact Us